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The purpose of this study was to evaluate the effect of n-3 polyunsaturated fatty acids (n-3 PUFAs) on normal tissue (lip mucosa) and
tumour growth when combined with ionising radiation. The oral region (snout) of C57 black mice was irradiated with 16.5Gy and n-
3 PUFAs (100ml) were injected intravenously for 2 weeks. After exposure to irradiation, the degree and duration of the acute
reactions decreased significantly when mice were treated with n-3 PUFAs as compared to the control group. Interestingly, the range
of the reactions in the n-3 PUFAs-treated group compared favourably to the group receiving amifostine (27.5mg/kg i.v.). the effect of
n-3 PUFAs was further evaluated in HEP-2 human carcinoma xenograft transplanted in nude mice. An inhibition of tumour growth
was observed when mice were treated with n-3 PUFAs alone and this effect was maximal when combined with irradiation. Similar
results were obtained using eicosapentaenoic acid. The effect of n-3 PUFAs was associated with inhibition of angiogenesis and
tumour proliferation, and significantly decreased expression of cyclooxygenase-2. In conclusion, n-3 PUFAs administration decrease
mucosal response, while moderately enhancing the antitumour effect of irradiation. The magnitude of the differential effect suggests
that n-3 PUFAs need to be further investigated in the clinic.
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The n-3 polyunsaturated fatty acids (PUFAs), including eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA), which
are present at high concentrations in some fish oils, have attracted
interest because of their importance in normal development
(Neuringer et al, 1988), and for their role as dietary supplements in
the prevention and treatment of chronic cardiovascular disease
(Simopoulos, 1991), the treatment of arthritic disorders (Kremer,
1991) and diabetes mellitus (Malasanos and Stacpoole, 1991).
These agents have been evaluated in various clinical trials in which
they have proved to be safe and well tolerated.
There is both epidemiologic and experimental evidence that n-3
PUFAs exert antitumour effects against some common cancers
such as breast, colon, and prostate (Rose and Connolly, 1999).
Multiple mechanisms are involved in this chemopreventive
activity, including suppression of neoplastic transformation
(Noguchi et al, 1997), cell cycle arrest (Albino et al, 2000),
induction of apoptosis (Latham et al, 1999), antiangiogenesis and
suppression of metastasis (Suzuki et al, 1997; Senzaki et al, 1998).
However, a common feature of most biological effects is the
inhibition of eicosanoid production from n-6 fatty acid precursors.
n-3 PUFAs also exert an anticachectic effect in the animal model of
hepatoma (Sauer et al, 1999; Smith et al, 1999).
Mechanistic experiments in vitro and in vivo support their
potential use as cancer chemopreventive agents, and may support
their use as auxiliary agents for cancer therapy. Since the
interaction of n-3 PUFAs and ionising radiation has not been
studied so far, the objective of the present study was to explore the
effect of n-3 PUFAs on normal tissue and tumour response, when
combined with ionising radiation.
MATERIALS AND METHODS
Reagents
The emulsion for perfusion, Omegaven
s, (Fresenius, Kabi,
France), containing 2% EPA and 2% DHA was used as a source
of n-3 PUFAs. The 20% Intralipide
s emulsion for perfusion
(Fresenius, Kabi, France), which contains 20% purified soja oil,
was used as a source of fatty acids devoid of n-3 PUFAs. Pure n-3
PUFAs, cis-5,8,11,14,17 EPA (Sigma Chemical Co., St Louis, MO,
USA), 99% pure, were complexed to BSA according to the method
described previously (Lai et al, 1996), aliquoted and stored at –
201C until use. Amifostine
s was purchased from (Schering-
Plough, Kenilworth, NJ, USA). Received 7 October 2002; revised 15 May 2003; accepted 22 May 2003
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HEP-2, a human head and neck cancer squamous cell line, was
maintained in RPMI 1640 medium (Sigma Chemical Co., St Louis,
MO, USA), supplemented with 10% fetal calf serum, penicillin
100mml
 1 and streptomycin 100mgml
 1,2 m ML -glutamine in a
5% carbon dioxide humidified incubator.
Animals
Female C57 black mice and BALB/c nude mice, 6–8-week old, were
purchased from Janvier CERT 53940 (Le Genest, St Isle, France).
During the experimental period, the animals were housed five to
seven per cage with sterilised white pine chip as bedding. The
animal room was kept in a specific pathogen-free condition, and
controlled for temperature (22721C), light (12-h) and humidity
(60710%). Animals used in this study were maintained in
facilities in accordance with current regulations and observing
‘Principles and Guidelines for the Use of Animals in Research’
Issued by the French government according to the European
community rules (Workman, 1998).
Diets
The experimental basal diet used in this study was food (R.03
U.A.R., F91360, Villemosson sur Orge). Fresh diet was provided,
and all remaining food was discarded, twice a week. Liquid food
was used in every group during the evaluation of mucosal
response. The liquid food (RENUTRYL
s 500, Nestle ´ Clinical
Nutrition, France) was substituted to the basal diet during the 3
weeks following irradiation.
Lip epidermal/mucosal reactions to ionising radiation
The oral region (snout) of female C57 black mice was selectively
irradiated with 225kV X-rays (HVL 0.5mm Cu, dose rate
0.7Gymin
 1 at 25.5cm from the target, 250kV Phillips). The
mice were irradiated without anaesthetic using a specially
constructed jig which held the mice tightly under the axillae,
allowing to hold the snout centrally. Five to six mice were
irradiated ventrally with a single dose of 16.5Gy, with the whole
body shielded by lead, except the anterior part of the snout.
Dosimetry was carried out using a small Farmer–Baldwin
ionisation chamber placed at the snout position within the mouse
jig. At the same time, 100ml of Omegaven
s was injected at the
inner epicanthus with anaesthesia over a period of 2 weeks, 5 times
a week. The same volume of Intralipide
s or amifostine crystalline
intraven (27.5mgkg) was used as a control. At first, the mice were
observed and weighted once every 2 days. After the appearance of
reactions on the transitional zone and epidermal surface of the
lips, they were routinely observed and the animals were weighted
daily. Lip epidermal/mucosal reactions were scored using the
Parkins scoring system giving a maximum score of 7 (Table 1)
(Parkins et al, 1983; Maggiorella et al, 2001).
Tumour irradiation procedure and response measurement
Three million cells in 0.1ml of HEP-2 were implanted subcuta-
neously into the right flank of nude Balb/c mice and the animals
were randomly allocated to control and treatment group when the
size of tumour reached a mean of 5mm, (n¼5). Two sources of n-
3 PUFAs were used for the study. We used a pure n-3 PUFA
solution as a positive control (pure EPA combined with bovine
serum albumin (BSA)) or the n-3 PUFAs alone or combined with
irradiation, injections were performed during 2 weeks, 5 times per
week. Irradiation consisted of a 15Gy dose delivered in two 7.5Gy
fractions to the tumour with a Philips RT 250radiation source
operating at 225kV X-rays with a 0.5mm Cu filter. Irradiation was
selectively delivered to the tumour by shielding the rest of the body
with lead. Tumour response was assessed from relative change in
the tumour volume in relation to the volume at the beginning of
therapy. The tumour volume was calculated from the greatest
transverse (width) and longitudinal (length) diameter of the
tumour using the formula: tumour volume¼length width
2/2
(Euhus et al, 1986). Measures were taken at the beginning of
treatment, at the end of treatment and then twice weekly for 7
weeks. The mice were inspected daily during the period of
experiment for any signs of disease or distress. At the end of the
observation period, mice were killed and tumours were removed
and processed for histopathological evaluation.
For tumour control probability evaluation, tumours were locally
irradiated at various doses in two fractions; pure n-3 PUFA
solution injections were performed during 2 weeks, 5 times per
week. Radiation doses yielding 50% tumour control at 90-day
values were computed by the logit method of analysis (Finnley,
1952).
Assessment of tumour vascularisation
To analyse the effect of n-3 PUFAs in HEP-2 tumour in vivo,w e
performed histological examination of tumour samples. Tumours
were collected on day 5 after the first injection of n-3 PUFAs and/
or irradiation. Immunohistochemistry was used to assess the
intratumoural vascularisation within the different experimental
groups. Tumour tissues were fixed in 100% ethanol embedded in
paraffin and 5-mm sections were prepared and routinely stained
with haematoxylin–eosin–saffranin. Endogenous peroxidase ac-
tivity was quenched by 3% H2O2 for 5min.
The sections were placed in coverplates (Shandon, Life Sciences
Technology, Cergy-Pontoise, France) and incubated with blocking
serum Optimax wash buffer 1:10 (BioGenex, San Ramon, CA,
USA) 10min. This step was followed by incubation with a mixture
of two rat primary antibodies raised against mouse platelet
endothelial cell adhesion molecule (Pecam1, PharMingen, Bec-
ton-Dickinson, France, #Mec13.3 and 390 clones) at a dilution of
1:50 for 1h. Slides were then incubated with a goat anti-rat biotin-
conjugated antibody 1:50 (PharMingen) and subsequently with
streptavidin-peroxidase (Dako, Trappes, France) 1:100 for 30min
and with the DAB Powervision kit (Immunovision Technologies
Microm, France) for 10min, counterstained with Mayer’s haema-
toxylin and mounted. Evaluation of tumour vascularisation was
achieved by selecting representative for semiquantitative assess-
ment of vascularisation, excluding necrotic and fibrotic areas.
Highly vascularised tumours exhibit microvessels within the
peripheral non-necrotic tumour area associated with a marked
fibrotic peritumoural vascular zone.
Tumours of intermediate level of vascularisation were associated
with an absence of vessels in the tumour itself, but with a
persistence of a well-vascularised fibrotic capsule.
Table 1 Parkins’ scoring system for lip reactions of mice
Oedema score
0.5 50–50 doubtful if any swelling
1 Slight but definite swelling
2 Severe swelling
Other scores
0.5 50–50 doubtful if abnormally pink
1 Slight but definite reddening
2 Severe reddening
3 Focal desquamation
4 Exudate or crusting involving about 1/2 lip area
5 Exudate or crusting involving more than 1/2 lip area
Separate scores for oedema (swelling) of lips, which is added to the other scores,
giving a total of seven maximum scores.
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absence of microvessels both within the tumour and at its
periphery.
Analysis of COX-2 expression by Western blot
HEP-2 cells were treated with 100nMml
 1 EPA and/or 5Gy
ionising irradiation for 48h. After rinsing with cold PBS, cells were
lysed with Tween-20 lysis buffer (50mM HEPES pH 7.4, 150mM
NaCl, 1mM EDTA, 1% NP-40, 1mM DTT, 50mM NaF, 1mM PMSF,
0.5mM Na3VO4), proteinases inhibitor and sonicated. Equal
amounts of proteins were analysed by 10% Sodium dodecyl
sulphate–polyacrylamide electrophoresis (SDS–PAGE). There-
after, proteins were transferred on to nitrocellulose membranes
and analysed using rabbit anti-COX-2, mouse b-actin. Proteins
were detected via incubation with horseradish peroxidase-con-
jugated secondary antibodies and the enhanced chemilumines-
cence detection system. b-Actin was used as a control for loading.
Reverse transcriptase–polymerase chain reaction for
COX-2
RNA isolation from HEP-2 was performed according to the
manufacturer’s protocol (Promega, Charbonieres, France). Ali-
quots from RNA were used for the detection of COX-2 and the
control b2 microglobulin mRNA (b2m). Total RNA was reverse-
transcribed with 5u of AMV reverse transcriptase for 45min at
481C. (PCR) reaction (941C for 30s, 601C for 1min, 681C for 2min
and an extension 721C for 10min) was carried out with 100mM
primers and 5U of Taq polymerase in 50ml. The COX-2 primer
pairs were 50-CGAGGTGTATGTATGAGTGTG-30, and 50-TCTAGC-
CAGAGTTTCACCGTA-30 generating a 550bp product (Subbara-
yan et al, 2001). The b2 microglobulin primer pairs consisted of 50-
CATTCGGGCCGAGATGTC-30 and 50-CTCCAGGCCAGAAAGA-
GAGAGTAG-30. A volume of 15ml of the Reverse transcriptase–
polymerase chain reaction for COX-2 (RT–PCR) products was
separated on a 1.5% agarose gel and visualised under ultraviolet
light.
Statistical analyses
Every 2 days, erythema-mucositis scores from day 6 to day 32 were
studied by a mixed model. Among mice treated by reverse
transcriptase (RT) alone and among mice treated by
RTþomegaven, the scores were significantly different between
the two experiments. Thus, the effect of omegaven was tested by a
mixed model comparing scores between mice treated by RT alone
and mice treated by RTþomegaven and taking into account the
experience effect.
Two other end points were studied: the duration between the
first day and the last day with a score equal or higher than 2 and
the maximum score reached during the follow-up period. The
comparison of these two criteria between the RT alone and
RTþomegaven was performed using the Wilcoxon nonparametric
rank test within each experience. These two criteria were also
compared between RTþamifostine and RTþomegaven groups.
RESULTS
Effect of n-3 PUFAs on lip epidermal/mucosal reactions to
X-irradiation
The mouse lip epidermal/mucosal reactions after irradiation with
16.5Gy began at 8 days, reached a peak between 12 and 16 days
and then returned to low values. The mixed model that studied
every 2 days erythema-mucositis scores from days 6 to 32 and
taking into account the experience effect showed that scores were
significantly lower in the RTþomega group than in the RT alone
group (P¼0.01). The degree and duration of these acute reactions
decreased significantly when mice were treated with n-3 PUFAs
(Tables 2 and 3). No effect was seen when mice were treated with
Intralipide
s Emulsion containing 20% soja oil (Figure 1). The
degree of epidermal/mucosal reactions decreased when mice were
treated with amifostine before irradiation. Figure 2 shows a
comparison between the effect of amifostine and n-3 PUFAs. The
radioprotective effect was slightly more pronounced in the n-3
PUFAs group than in the amifostine group, although not
statistically different (Table 3).
Table 2 Description of the Wilcoxon nonparametric rank test
Duration of score X2 (days) Maximum score
Median (range) Median (range)
RT experiment 1
(n¼5)
14 (11–16) 5.5 (4.5–6)
RT experiment 2
(n¼5)
8(7–9) 6 (5–7)
RT+intralipid
experiment 1 (n¼5)
11 (8–15) 5 (5–6)
RT+amifostine
experiment 2 (n¼4)
9 (8–10) 3.5 (3–4)
RT+omegaven
experiment 1 (n¼5)
6 (4–8) 2.5 (2.5–3.5)
RT+omegaven
experiment 2 (n¼6)
7(5–8) 4 (4–5)
RT¼reverse transcriptase.
Table 3 P-value of Wilcoxon non parametric rank test
Duration of score X2 Maximum score
Rt vs RT+omegaven
Experiment 1 0.03 0.03
Experiment 2 0.18 0.03
RT+amifostine vs
RT+omegaven
(experiment 2)
0.054 0.10
RT vs RT+intralipid
(experience 1)
0.24 0.92
RT vs RT+ amifostine
(experience 2)
0.27 0.046
RT¼reverse transcriptase.
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Figure 1 Epidermal/mucosal lip reaction scores in mice, which were the
mean of two experiments for irradiation alone (16.5Gy) and for irradiation
plus Intralipid (soja oil) and irradiation plus n-3 PUFAs.
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As shown in Figure 3, a moderate tumour growth inhibition was
observed in mice receiving an injection of n-3 PUFAs or
irradiation alone, compared to the control group. The growth rate
of the tumour in the combined group was lower than in the n-3
PUFAs alone group or irradiation alone group. A comparable
inhibitor effect on tumour growth was observed when mice were
treated with pure EPA (data not shown). However, the differences
in tumour growth retardation did not reach significance (P¼0.14
using Wilcoxon’s nonparametric rank test). No significant toxicity
or side effects were observed in the various treatment groups (data
not shown) (Figure 4).
The histological examination of the tumours showed a typical
viable squamous cell carcinoma with various degrees of necrosis in
the control group, fewer focal areas of viable cells surrounded by
fibrocytes in the n-3 PUFAs group and almost undetectable
tumour cells in the group of n-3 PUFAs plus irradiation (Figure 5).
Immunohistochemical staining with mouse anti-CD31 antibody
indicated that n-3 PUFAs significantly inhibit the tumour, whcih
was highly vascularised with thick and large vascular channels in
the control group, moderately vascularised in the irradiation alone
and the n-3 PUFAs groups. The formation of angiogenesis was
markedly inhibited in the n-3 PUFAs combined with the
irradiation group (Figure 6).
Decreased expression of COX-2
Several potential molecular markers were studied in HEP-2 cells,
including COX-2 expression for which significant changes were
observed. Cells were treated with EPA 100mgml
 1 and/or 5Gy
irradiation for 48h. COX-2 protein was upregulated by irradiation
in a time-responsive manner, but it was downregulated by EPA in
a concentration-responsive and time-responsive manner (data not
shown). Figure 7 illustrates the expression of COX-2 proteins, as
determined by Western immunoblot analysis in HEP-2 cells. The
downregulation of COX-2 was more pronounced when combined
with irradiation. Further study using RT–PCR showed that EPA
was able to inhibit COX-2 expression at the transcriptional level
(Figure 8).
DISCUSSION
Both epidemiologic and experimental studies have suggested that
n-3 PUFAs can exert a chemopreventive effect against some
common tumours and multiple mechanisms have been involved in
this activity, including suppression of neoplastic transformation
(Noguchi et al, 1997), cell cycle arrest (Albino et al, 2000),
induction of apoptosis (Latham et al, 1999), antiangiogenesis and
suppression of metastasis (Ligo et al, 1997; Senzaki et al, 1998).
This study was designed to assess the possible interaction of n-3
PUFAs and ionising radiation, which has not been reported before.
The n-3 PUFAs were found to decrease the mucosal/epidermal
response of irradiation (Figures 1 and 2). The mechanisms
involved in the protection of the mucosa from irradiation are
not known. Interestingly, the effect was of the same magnitude as
that observed with amifostine, which is so far one of the most
efficient radioprotective agents. It has been reported that the n-3
PUFAs are immunomodulatory and have been shown to suppress
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Figure 2 Epidermal/mucosal lip reaction scores in mice; P¼0.0002 for
irradiation alone and irradiation plus amifostine; Po0.0001 for irradiation
alone and irradiation plus n-3 PUFAs.
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Figure 3 Change in tumour volume of tumour xenografts (HEP-2) in
nude mice irradiated (RT) to a total dose of 15Gy in two fractions of
7.5Gy. Values at each point are the mean ratios of the observed tumour
volume at a considered time divided by the initial tumour volume. Error
bars represent the mean7the standard error of the ratio.
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Figure 4 Tumour control probability at 90 days for 8mm diameter
HEP-2 tumours according to the radiation dose for animals treated with
irradiation alone (dark triangles), or irradiation and n-3 PUFA (dark
squares). Clear triangles and clear square, respectively, represent the dose
curing 50% of the animals for irradiation alone and irradiation plus n-3
PUFA; error bars show the 95% confidence interval.
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sendotoxin-induced production of proinflammatory cytokines such
as IL-1 and tumour necrosis factor (TNF) by peripheral blood
mononuclear cells (PBMC) from healthy volunteers (Meydani et al,
1993). Studies of weight-losing pancreatic cancer patients receiving
high-purity EPA have demonstrated suppression of PBMC IL-6
production (Wigmore et al, 1997). Serhan et al (2000) have
reported that n-3 PUFA exerts antimicroinflammatory lipid signals
via COX-2, which might be involved in its radioprotective action.
Figure 5 Detection of vessels within the tumour of HEP-2 tumour xenograft: Pecam-1 endothelial immunostaining, magnification  100. (A) Control
group, highly vascularised tumour with thick and large vascular channels. Presence of large vessels located at the periphery of the tumour. (B) Irradiation
alone, moderately vascularised tumours. (C) n-3 PUFA alone, moderately vascularised tumours. (D) Irradiation combined with n-3 PUFA, marked inhibition
in tumour vascularisation.
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Figure 6 Evaluation of the degree of tumour vascularisation in HEP-2
tumour xenograft according to the scoring of HEP-2 tumours from 20
animals that were either untreated, treated by radiation alone, n-3 PUFA
alone or both. The diagram shows the mean scoring for each group, error
bars represent the standard error. Differences between the irradiation
group and irradiation plus n-3 PUFA were statistically significant, Po0.05.
12 34
Cox-2
β-Actin
Figure 7 Representative Western blot expression of COX-2 and
protein in HEP-2 cells were treated with EPA (pure n-3 PUFA) 100mgml
 1
and/or irradiated with 5Gy. The interval for combined treatment was 24h.
All cells were harvested at 48h treatment. Lane 1: control, lane 2: n-3
PUFAs 100mgml
 1, lane 3: irradiation with 5Gy plus n-3 PUFAs
100mgml
 1, lane 4: 5Gy irradiation.
Tubulin
COX-2
12 3 4  
Figure 8 Expression of COX-2 mRNA in HEP-2. HEP-2 cells were
treated with EPA 100mgml
 1 and/or irradiated with 5Gy. The interval for
combined treatment was 24h. All cells were harvested at 48h after
treatment. Lane 1: control, lane 2: n-3 PUFAs 100mgml
 1, lane 3: n-3
PUFAs 100mgml
 1þ5gy, lane 4: 5Gy irradiation alone.
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was essential to determine whether these agents could also exert a
tumour protection after irradiation. Interestingly, no tumour
protection was observed in HEP-2 squamous cell carcinoma
tumour, whereas a moderate antiproliferative effect of n-3 PUFAs
was found with the suggestion that the combination of n-3 PUFAs
and ionising radiation led to a more important growth delay than
ionising radiation alone. This effect might be mediated by several
modifications induced by n-3 PUFAs including COX-2 inhibition,
downregulation of the antiapoptotic bcl-2 gene and finally by an
antiangiogenic effect (Figures 5 and 6).
In contradiction with previous reports, we did not find a
significant antiangiogenic effect of n-3 PUFAs when given alone;
this might be related to the relatively short period of overall n-3
PUFAs administration in our study.
The observed n-3 PUFAs induced downregulation of mRNA
transcriptional level and protein COX-2, which is in good
agreement with previous reports that a short-term dietary
intervention in men with prostate cancer led to a significant
increase in omega-3/omega-6 fatty acid ratios in adipose tissue,
and the potential for the diet to prevent the development and
progression of prostate cancer by way of altered expression of
COX-2 expression in prostatic tissue specimen which was
determined by semiquantitative RT–PCR (Aronson et al, 2001).
In addition, modulation of n-3 PUFAs production via the influence
on COX-2 activity and the suppression of apoptosis may also play
a key role in high-fat mixed lipids diet-induced rat colon
tumorigenesis (Rao et al, 2001). Our study is in agreement with
these data and is the first to show that n-3 PUFAs were able to
enhance the antitumour effect of radiation therapy partly by
decreasing the expression of COX-2 induced by irradiation.
In conclusion, our findings indicated that n-3 PUFAs decrease
mucosal/epidermal reactions of ionising radiation with the same
magnitude as that of a reference radioprotective agent, amifostine,
while enhancing the antitumour effect of radiation therapy. The
antitumour effect was associated with the inhibition of angiogen-
esis and tumour proliferation, and a decreased expression of COX-
2. The results of this study strongly suggest that the combination of
n-3 PUFAs and ionising radiation should be further tested in
patients.
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